Q-omics provides the consensus-scored NEUROD1 profile across patient tissues and cancer cell-line models. NEUROD1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NEUROD1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, NEUROD1 RNA expression shows 8,579 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where NEUROD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEUROD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEUROD1 survival associations across molecular data types. NEUROD1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEUROD1 RNA expression–survival associations across cancer types. High NEUROD1 expression shows unfavorable associations in KIRC, ACC, KICH and MESO, but favorable associations in GBM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NEUROD1 RNA expression.
This table summarizes NEUROD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NEUROD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEUROD1 shows lower tumor expression in COAD, KIRC, KIRP, READ, STAD and KICH. The COAD box plot shows higher NEUROD1 RNA expression in normal versus tumor tissue (log2 FC = −1.188, t-test p < 0.001).
This table shows molecular features associated with NEUROD1 in patient tissues and cancer cell lines. In patient samples, NEUROD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NEUROD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
